AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing ...
AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351 (k) biosimilar pathway, today announced that ...
Rumble Closes $775 Million Strategic Investment from Tether and Related Tender Offer
As part of the transaction Tether purchased 103,333,333 shares of Rumble Class A Common Stock at a price per share of $7.50, totaling $775 million in gross proceeds to Rumble. The Company will use ...